In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

Exact presentation times are subject to change. Expected presentation times can be found on the Program section of the Angiogenesis, Exudation, and Degeneration 2025 conference website. Follow the ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Fundus photography involves taking a photo of the back of the eye to detect signs of diabetic retinopathy. It is also possible to capture an image of the retina using a smartphone. Diabetic ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

LifeStyles SKYN condoms are the original brand of non-latex condoms. These condoms are made of polyisoprene, a synthetic form of natural rubber latex. Polyisoprene is safe for those with a latex ...

A case report demonstrates independent effect of GLP-1 receptor agonist.

Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase II drugs for ...

Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in Phase III for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase III drugs for ...